FGFR1 and central nervous system cancer: Low-grade gliomas with duplication of FGFR1 TKD or MYB overexpression show activation of the MAPK/ERK and PI3K pathways, showing expression profiles similar to those of pilocytic astrocytomas with BRAF fusions and suggest that these pathways may represent potentially important therapeutic targets [129].